Form 4: Tarsus Pharmaceuticals Director Andrew Goldberg Reports Acquisition of Stock Options and Restricted Stock Units

Director Andrew Goldberg reports acquisition of stock options and restricted stock units in Tarsus Pharmaceuticals, Inc. following the company's annual meeting of stockholders.

Summary

• Andrew D. Goldberg, a director of Tarsus Pharmaceuticals, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• On June 13, 2024, Goldberg acquired 5,000 stock options with an exercise price of $33.14, vesting fully on June 12, 2034, contingent upon continuous service.
• Goldberg also acquired 3,350 restricted stock units (RSUs), each representing a right to receive one share of common stock, vesting fully on the one-year anniversary of the grant date, also contingent upon continuous service.
• Following these transactions, Goldberg directly owns 5,000 stock options and 3,350 RSUs.
• Goldberg has granted a Power of Attorney to Bobak Azamian, Jeffrey Farrow, Bryan Wahl, Scott Sieckert, Shannon Callan, and Kristine Mengoli to execute and file necessary forms with the SEC.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and RSUs by a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting conditions tied to continuous service align the director's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects, but the vesting of the options and RSUs is contingent on continued service.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership structure and alignment of interests between management and shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, aligning their interests with shareholder value.
• Vesting schedules tied to continued service are also common, incentivizing long-term commitment.
• Companies like Alnylam Pharmaceuticals, Vertex Pharmaceuticals, and BioMarin Pharmaceutical also use similar equity-based compensation for their directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it indicates director alignment with company performance.

Key Dates